Sea Pharmaceuticals announced its selection of Inotiv (NOTV) for pre-clinical development IND-enabling studies to support the advancement of Sea’s lead molecule SPM-0404 as a potential new oral medicine to treat tinnitus, epilepsy and S-ALS. Sea’s SPM-0404 and a second-generation molecule SPM-0606 represent a portfolio strategy of discovery and development of potent, selective, CNS-penetrant molecules targeting excitatory glutamate neurotransmission. A 100% Sea-owned patent estate protects Sea’s novel chemical composition of matter in separate filings.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NOTV: